

# Petcam<sup>®</sup>



## SCHEDULING STATUS:

S3

## COMPOSITION:

Each ml contains 1.5 mg meloxicam BP.

One drop contains 0.05 mg meloxicam BP.

Preservative: Sodium benzoate 0.15% w/v

## PHARMACOLOGICAL CLASSIFICATION:

C 3.1.2.2 Selective COX-2 inhibitors.

## PHARMACOLOGICAL ACTION:

Meloxicam, a non-steroidal anti-inflammatory compound, belongs to the oxicam group which acts by inhibition of prostaglandin synthesis. It has analgesic, antipyretic and anti-inflammatory properties, inhibits leukocyte infiltration into inflamed tissue and prevents bone and cartilage degradation. To a lesser extent it inhibits collagen-induced thrombocyte aggregation.

Following oral administration meloxicam is completely absorbed and reaches maximal plasma concentrations between 2 and 4.5 hours. Repeated once daily administration of meloxicam will result in steady state concentrations within 3 to 5 days.

A linear relationship exists between the dose administered and plasma concentration observed in the therapeutic dose range. Approximately 97% of meloxicam is plasma protein bound. Meloxicam is predominant in plasma (> 80%). Urine, bile and faeces contain only traces of the parent compound. It undergoes metabolism to an alcohol, an acid derivative and to several polar metabolites. All major metabolites are pharmacologically inactive.

The elimination half-life of meloxicam is 24 hours. Approximately 75% of the administered dose undergoes excretion via faeces and 25% via urine, mostly in the form of pharmacologically inactive metabolites.

## INDICATIONS:

PETCAM is indicated for the relief of pain and inflammation related to musculoskeletal disorders including discospondylitis, soft tissue injuries and arthropathies in dogs.

## CONTRA-INDICATIONS:

The use of PETCAM should be avoided following pretreatment with other steroidal or non-steroidal anti-inflammatory drugs, anti-coagulants or aminoglycoside antibiotics. It should not be used concurrently with the abovementioned drugs. It is contra-indicated in animals diagnosed with hepatic, cardiac or clinical renal disease, gastro-intestinal ulceration, a haemorrhagic diathesis or hypersensitivity to the product.

## WARNINGS:

PETCAM should be used with caution in any animal less than 6 weeks of age or in debilitated aged animals due to additional risk. If use in such animals is unavoidable a reduced dosage and careful clinical management is required.

## PREGNANCY AND LACTATION:

PETCAM should not be given to pregnant or lactating bitches.

## DOSAGE AND DIRECTIONS FOR USE:

PETCAM can be administered mixed with food or given orally.

	<b>Dosage in mg/kg bodyweight</b>	<b>Dosage using graduated syringe provided</b>	<b>Dosage using the drop dispenser</b>
<b>Day 1 of treatment</b>	0.2mg/kg	<b>Double the weight of the dog</b>	<b>4 drops per kg body weight</b>
<b>Day 2 and consecutive days of treatment (medium to long term use)</b>	0.1mg/kg	<b>According to weight of the dog</b>	<b>2 drops per kg body weight</b>

The suspension can be given using the graduated syringe which provides an automatic measure of PETCAM according to the animal's weight or the drop dispenser which delivers 0.05mg of meloxicam per drop. Use according to the instructions given by the veterinarian. A clinical response is usually seen within 3 to 4 days. Treatment should be discontinued after 10 days should no improvement be noticeable.

**DIRECTIONS FOR USE:**

- Shake well.
- Remove the child proof screw top cap by pressing down firmly and simultaneously turning anti-clockwise.
- Insert syringe into top of bottle and invert.
- Pull the plunger back to the approximate volume required.
- Adjust dosage volume to the corresponding body weight.
- Twist the bottle and the syringe in opposite directions and pull apart.
- Empty the contents of the syringe over the food or administer orally.

**SIDE-EFFECTS AND SPECIAL PRECAUTIONS:**

Side-effects may include depression, vomiting, diarrhoea, occult blood in the faeces and loss of appetite. In the case of gastro-intestinal side-effects, treatment should be discontinued. Gastro-intestinal side-effects are usually transient and disappear following termination of treatment. In rare cases they may be serious.

**KNOWN SIGNS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT:**

Treatment is symptomatic and supportive.

**IDENTIFICATION:**

Pale green coloured, uniform suspension.

**PRESENTATION:**

10ml, 32ml and 100ml white plastic squeeze dropper bottle with a white cap and a graduated dosing plastic syringe.

**STORAGE INSTRUCTIONS:**

Store below 25 °C.

Keep out of reach of children and uninformed persons.

**REGISTRATION NUMBER:**

05/3.1.2.2/3

**REGISTRATION HOLDER:**

Cipla Vet (Pty) Ltd.

Co. Reg. No. 2001/017471/07

PO Box 1096, Durbanville, 7551

Tel: 0861 115 037

Fax: 0861 115 038